DHR vs NVS
Danaher Corporation vs Novartis AG — AI-powered side-by-side comparison
DHR
Danaher Corporation
63
Buy
VS
| Metric | DHR | NVS |
|---|
| AI Score |
63
|
64
|
| Price |
$204.80
|
$156.34
|
| P/E Ratio |
36.24×
|
23.66×
|
| ROE |
6.9%
|
30.5%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
58.5%
|
74.3%
|
| Debt / Equity |
0.51×
|
1.18×
|
| Dividend Yield |
0.7%
|
2.9%
|
| RSI (14) |
67.2
|
55.8
|
| Beta |
0.823
|
0.46
|
| Expected Upside |
+1.6%
|
+2.7%
|
AI Committee View
Current Innellis committee reasoning for DHR versus NVS.
NVS leads by 1 points.
NVS scores 64/100 (Buy) versus DHR at 63/100 (Buy).
DHR Committee View
80% agreement
5 analysts
The primary driver is market regime is bullish (bull market -- normal position sizing). The main limiting factor is p/e of 35.9 is moderate-to-rich. The committee is constructive but not yet at full conviction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- MACD histogram positive -- bullish momentum — Technical
- Weekly trend (sideways) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- P/E of 35.9 is moderate-to-rich — Value
NVS Committee View
67% agreement
6 analysts
The primary driver is news sentiment is positive (+0.67 across 9 articles, 14d). The main limiting factor is price-to-book of 5.6x prices in significant intangible value. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 29.9% shows genuine earnings power backing the valuation — Value
- Dividend yield of 3.0% pays you to wait — Value
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- Price-to-book of 5.6x prices in significant intangible value — Value
- EPS declining -3.5% YoY despite any revenue growth — Growth
- MACD histogram negative -- bearish momentum — Technical